The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...
Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...
Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen ...
Merck & Company Inc (NYSE:MRK) has ceased discussions to acquire biotechnology firm Revolution Medicines Inc (NASDAQ:RVMD), following a failure to reach an agreement on the company’s valuation.
The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...
Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...
The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results